TN2011000053A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2011000053A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; compounds; phosphatidylinositol; kinase; substituents
Prior art date: 2008-09-10

Application number

TN2011000053A

Other languages

English (en)

Inventor

Giorgio Caravatti

Pascal Furet

Robin Alec Fairhurst

Vito Guagnano

Patricia Imbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-10

Filing date

2011-01-31

Publication date

2012-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-31 Application filed by Novartis Ag filed Critical Novartis Ag

2012-09-05 Publication of TN2011000053A1 publication Critical patent/TN2011000053A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)

TN2011000053A 2008-09-10 2011-01-31 Organic compounds TN2011000053A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08164104		2008-09-10
US9667408P	2008-09-12	2008-09-12
PCT/EP2009/061644 WO2010029082A1 (fr)	2008-09-10	2009-09-08	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2011000053A1 true TN2011000053A1 (en)	2012-09-05

Family

ID=40350060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000053A TN2011000053A1 (en)	2008-09-10	2011-01-31	Organic compounds

Country Status (50)

Country	Link
US (4)	US8227462B2 (fr)
EP (1)	EP2331537B1 (fr)
JP (1)	JP5486601B2 (fr)
KR (1)	KR101290844B1 (fr)
CN (1)	CN102149711B (fr)
AR (2)	AR073369A1 (fr)
AU (1)	AU2009290904B2 (fr)
BR (1)	BRPI0918750B8 (fr)
CA (1)	CA2734819C (fr)
CL (1)	CL2011000504A1 (fr)
CO (1)	CO6351738A2 (fr)
CR (1)	CR20110059A (fr)
CU (1)	CU24000B1 (fr)
CY (2)	CY1117078T1 (fr)
DK (1)	DK2331537T3 (fr)
DO (1)	DOP2011000070A (fr)
EA (1)	EA018863B1 (fr)
EC (1)	ECSP11010880A (fr)
ES (1)	ES2560673T3 (fr)
FI (1)	FIC20200046I1 (fr)
GE (1)	GEP20135991B (fr)
HN (1)	HN2011000699A (fr)
HR (1)	HRP20160014T1 (fr)
HU (2)	HUE025884T2 (fr)
IL (1)	IL210976A (fr)
JO (1)	JO3121B1 (fr)
LT (1)	LTC2331537I2 (fr)
LU (1)	LUC00186I2 (fr)
MA (1)	MA32604B1 (fr)
ME (1)	ME01284B (fr)
MX (1)	MX2011002597A (fr)
MY (1)	MY151556A (fr)
NI (1)	NI201100049A (fr)
NL (1)	NL301071I2 (fr)
NO (1)	NO2020037I1 (fr)
NZ (1)	NZ590754A (fr)
PA (1)	PA8841901A1 (fr)
PE (1)	PE20110796A1 (fr)
PL (1)	PL2331537T3 (fr)
PT (1)	PT2331537E (fr)
RS (1)	RS54476B1 (fr)
SI (1)	SI2331537T1 (fr)
SM (1)	SMP201100019B (fr)
SV (1)	SV2011003853A (fr)
TN (1)	TN2011000053A1 (fr)
TW (1)	TWI453206B (fr)
UA (1)	UA104147C2 (fr)
UY (1)	UY32096A (fr)
WO (1)	WO2010029082A1 (fr)
ZA (1)	ZA201100699B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
CA2729914A1 (fr)	2008-07-11	2010-01-14	Novartis Ag	Combinaison de (a) un inhibiteur de phosphoinositide 3-kinase et de (b) un modulateur de voie ras/raf/mek
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR101854484B1 (ko) *	2010-11-08	2018-05-03	노파르티스 아게	Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료에서의 2-카르복사미드 시클로아미노 우레아 유도체의 용도
AU2015203865B2 (en) *	2010-11-08	2016-11-03	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk) *	2011-03-03	2016-09-26	Новартіс Аг	Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
CA2833962A1 (fr) *	2011-04-25	2012-11-01	Novartis Ag	Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
WO2012175522A1 (fr)	2011-06-21	2012-12-27	Novartis Ag	Polymorphes du 2-amide-1-({4-méthyl-5-[2-(2,2,2-trifluoro-1,1-diméthyl- éthyl)pyridin-4-yl]-thiazol-2-yl}-amide d'acide (s)-pyrrolidine-1,2-dicarboxylique
UA114178C2 (uk) *	2011-07-01	2017-05-10	Новартіс Аг	Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
AU2012333092B2 (en) *	2011-08-31	2016-04-21	Novartis Ag	Synergistic combinations of PI3K- and MEK-inhibitors
WO2013049581A1 (fr) *	2011-09-30	2013-04-04	Beth Israel Deaconess Medical Center Inc.	Compositions et méthodes de traitement de maladies de prolifération
AU2012322976B2 (en)	2011-10-14	2016-05-12	Novartis Ag	2 - carboxamide cycloamino urea derivatives in combination with Hsp90 inhibitors for the treatment of proliferative diseases
US20140288073A1 (en)	2011-10-28	2014-09-25	Novartis Ag	Method of Treating Gastrointestinal Stromal Tumors
MX2014005414A (es)	2011-11-02	2014-09-22	Novartis Ag	Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf).
BR112014020773A2 (pt)	2012-02-22	2020-10-27	Sanford-Burnham Medical Research Institute	compostos de sulfonamida e seus usos como inibidores tnap
US9795596B2 (en) *	2012-03-29	2017-10-24	Novartis Ag	Pharmaceutical diagnostic
RU2014143232A (ru) *	2012-03-30	2016-05-27	Новартис Аг	Соединения для применения в лечении нейробластомы, саркомы юинга или рабдомиосаркомы
EP2852661A1 (fr)	2012-05-23	2015-04-01	F. Hoffmann-La Roche AG	Compositions et procédés d'obtention et d'utilisation de cellules endodermiques et d'hépatocytes
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
PE20191655A1 (es)	2012-08-07	2019-11-07	Novartis Ag	Combinaciones farmaceuticas
EP2885003B1 (fr) *	2012-08-16	2021-09-29	Novartis AG	Combinaison de pi3k inhibiteur et de c-met inhibiteur
MX356278B (es) *	2012-09-20	2018-05-22	Novartis Ag	Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.
US9732032B2 (en) *	2012-11-16	2017-08-15	Merck Patent Gmbh	3-aminocyclopentane carboxamide derivatives
EP2742940B1 (fr)	2012-12-13	2017-07-26	IP Gesellschaft für Management mbH	Sel de fumarate de (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane destinés à être administrés une fois par jour, deux fois par jour ou trois fois par jour
JP6307096B2 (ja) *	2013-01-23	2018-04-04	アストラゼネカアクチボラグ	化合物
HK1214533A1 (zh)	2013-03-15	2016-07-29	基因泰克公司	治疗癌症和预防癌症耐药性的方法
SG11201507730UA (en) *	2013-03-21	2015-10-29	Novartis Ag	Combination therapy comprising a b-raf inhibitor and a second inhibitor
EP2981261A1 (fr) *	2013-04-05	2016-02-10	Sanofi	Composition anti-tumorale comprenant un inhibiteur sélectif de pi3k bêta et un inhibiteur sélectif de pi3k alpha
US20160095842A1 (en)	2013-05-31	2016-04-07	Christine Fritsch	Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
JP2016520662A (ja)	2013-06-11	2016-07-14	ノバルティスアーゲー	Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ
BR112015030578A2 (pt)	2013-06-18	2017-07-25	Novartis Ag	combinações farmacêuticas
RU2016107813A (ru)	2013-08-08	2017-09-14	Новартис Аг	Комбинации ингибиторов киназы pim
MX384403B (es)	2013-08-14	2025-03-14	Novartis Ag	Terapia de combinación para el tratamiento del cáncer.
WO2015048312A1 (fr)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Méthodes de traitement de cancers hématologiques
CN105979947A (zh) *	2013-12-06	2016-09-28	诺华股份有限公司	α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
RU2020121929A (ru)	2014-01-15	2020-07-13	Новартис Аг	Фармацевтические комбинации
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015216590A1 (en)	2014-02-11	2016-06-30	Novartis Ag	Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer
UY36032A (es)	2014-03-14	2015-10-30	Novartis Ag	Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
EP3659621A1 (fr)	2014-09-13	2020-06-03	Novartis AG	Polythérapies contre le cancer
US20170296523A1 (en)	2014-10-03	2017-10-19	Frantz ELBAZ	Pharmaceutical Compositions Comprising Alpelisib
EP3200775B1 (fr)	2014-10-03	2019-11-20	Novartis AG	Polythérapies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX389663B (es)	2014-10-14	2025-03-20	Novartis Ag	Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
CN104844589B (zh) *	2014-12-26	2018-04-20	中国科学院合肥物质科学研究院	一种pi3k激酶抑制剂
MY190404A (en)	2015-03-10	2022-04-21	Aduro Biotech Inc	Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US10130629B2 (en)	2015-03-25	2018-11-20	Novartis Ag	Pharmaceutical combinations
WO2017001362A1 (fr)	2015-06-29	2017-01-05	F. Hoffmann-La Roche Ag	Méthodes de traitement avec du tasélisib
MA42295B1 (fr)	2015-07-02	2020-02-28	Hoffmann La Roche	Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
CN107921026A (zh) *	2015-08-28	2018-04-17	诺华股份有限公司	药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用
EP3340991A1 (fr)	2015-08-28	2018-07-04	Novartis AG	Combinaisons de l'inhibiteur de cdk4/6 lee011 et de l'inhibiteur de mek1/2 trametinib, comprenant éventuellement en outre l'inhibiteur de pi3k byl719 pour traiter le cancer
EP3340987A1 (fr)	2015-08-28	2018-07-04	Novartis AG	Combinaison de ribociclid et de dabrafenib pour le traitement ou la prévention du cancer
JP2018528949A (ja)	2015-08-28	2018-10-04	ノバルティスアーゲー	Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法
EP3340986A1 (fr)	2015-08-28	2018-07-04	Novartis AG	Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpelisib et l'inhibiteur de cdk4/6 ribociclib et son utilisation dans le traitement/la prévention du cancer
AU2016314082B2 (en)	2015-08-28	2019-07-25	Novartis Ag	Mdm2 inhibitors and combinations thereof
TW201726140A (zh)	2015-09-17	2017-08-01	瑞典商阿斯特捷利康公司	治療癌症之新型生物標記及方法
CN105294546B (zh) *	2015-10-29	2017-12-08	天津市斯芬克司药物研发有限公司	一种吡啶化合物及其制备方法
AU2016347881A1 (en)	2015-11-02	2018-05-10	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
ES2908376T3 (es)	2015-11-03	2022-04-28	Janssen Biotech Inc	Anticuerpos que se unen específicamente a PD-1 y usos de los mismos
CA3006419A1 (fr)	2015-12-03	2017-06-08	Novartis Ag	Traitement du cancer avec un inhibiteur de pi3k chez un patient preselectionne comme ayant une mutation de pik3ca dans l'adntc
CN108495651A (zh)	2015-12-17	2018-09-04	诺华股份有限公司	抗pd-1的抗体分子及其用途
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018060833A1 (fr)	2016-09-27	2018-04-05	Novartis Ag	Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018092064A1 (fr)	2016-11-18	2018-05-24	Novartis Ag	Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl
CN106674200B (zh) *	2016-12-21	2019-04-12	西安交通大学	一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
KR20200021087A (ko)	2017-06-22	2020-02-27	노파르티스 아게	Cd73에 대한 항체 분자 및 이의 용도
EP3642240A1 (fr)	2017-06-22	2020-04-29	Novartis AG	Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
EP3694511A1 (fr)	2017-10-13	2020-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polythérapie du cancer du pancréas
WO2019101871A1 (fr)	2017-11-23	2019-05-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Nouveau marqueur permettant de prédire la sensibilité à des inhibiteurs de pi3k
CN111386113A (zh)	2017-12-01	2020-07-07	诺华股份有限公司	包含lsz102和阿培利司的药物组合
CA3085006A1 (fr) *	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Procedes pour preparer des modulateurs du regulateur de la conductance transmembranaire de la mucoviscidose
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
PE20251292A1 (es)	2018-03-08	2025-05-14	Incyte Corp	Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
EP3805231B1 (fr)	2018-05-30	2024-10-16	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Inhibiteur contenant un dérivé tricyclique, son procédé de préparation et son application
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2020010003A1 (fr)	2018-07-02	2020-01-09	Incyte Corporation	DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
US20220047567A1 (en) *	2018-09-10	2022-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of neurofibromatosis
AU2019355574A1 (en)	2018-10-05	2021-05-06	Sloan-Kettering Institute For Cancer Research	PI3K inhibitors and uses thereof
TW202038957A (zh)	2018-12-21	2020-11-01	日商第一三共股份有限公司	抗體-藥物結合物與激酶抑制劑之組合
WO2020228729A1 (fr)	2019-05-13	2020-11-19	罗欣药业(上海)有限公司	Forme cristalline de composé quinazolinone et son procédé de préparation
CN120172965A (zh) *	2019-05-27	2025-06-20	君实润佳(上海)医药科技有限公司	含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001431A1 (fr)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas
US20220354452A1 (en)	2019-07-02	2022-11-10	Inserm (Institut National De La Santé Et De La Rechrche Médical)	Use of ultrafast elasticity imaging for detecting pancreatic cancers
EP3993786A1 (fr)	2019-07-02	2022-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de traitement prophylactique du cancer chez des patients souffrant de pancréatite
CN114302722A (zh)	2019-07-07	2022-04-08	奥列马制药公司	雌激素受体拮抗剂方案
CA3152401A1 (fr)	2019-08-26	2021-03-04	Arvinas Operations, Inc.	Procedes de traitement du cancer du sein avec des derives de tetrahydronaphtalene en tant qu'agents de degradation du recepteur des estrogenes
WO2021053559A1 (fr)	2019-09-18	2021-03-25	Novartis Ag	Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
KR20220119610A (ko)	2019-11-25	2022-08-30	상하이 한서 바이오메디컬 컴퍼니 리미티드	3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
CN113045564B (zh) *	2019-12-27	2024-09-20	上海天慈国际药业有限公司	一种阿培利司的制备方法
CN115835888A (zh) *	2020-03-25	2023-03-21	润佳（苏州）医药科技有限公司	酰胺官能团中的稳定重同位素及其用途
WO2022016420A1 (fr) *	2020-07-22	2022-01-27	罗欣药业(上海)有限公司	Forme cristalline d'un composé quinazolinone, son procédé de préparation et son utilisation
JP2024516006A (ja)	2021-05-03	2024-04-11	ノバルティスアーゲー	アルペリシブ製剤
CN115611883B (zh) *	2021-07-13	2025-03-28	生物岛实验室	一种双环结构的PI3Kα抑制剂及其制备方法和用途
CA3237812A1 (fr) *	2021-11-12	2023-05-19	Biopolar Youtang (Guangdong) Pharmaceutical Co., Ltd.	Inhibiteur de drak2, son procede de preparation et son utilisation
EP4230196A1 (fr)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Composés à utiliser dans le traitement des dystrophinopathies
CN120390748A (zh)	2022-10-28	2025-07-29	国家健康医学研究所	磷脂酰肌醇3-激酶的新型抑制剂
WO2024100236A1 (fr)	2022-11-11	2024-05-16	Astrazeneca Ab	Polythérapies pour le traitement du cancer
CN116239591B (zh) *	2023-02-14	2025-09-23	嘉兴大学	一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
TW202440096A (zh)	2023-03-24	2024-10-16	美商亞文納營運公司	雌激素受體降解劑之給藥方案
CN116987072A (zh) *	2023-07-27	2023-11-03	武汉呈瑞生物医药科技有限公司	化合物及其应用
WO2025181153A1 (fr)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Utilisation d'inhibiteurs d'atr en combinaison avec des inhibiteurs de pi3k alpha
EP4643858A1 (fr) *	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Procédés et composition pharmaceutique pour le traitement d'une maladie utérine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649146A (en)	1983-01-31	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de)	1987-02-05	1988-08-18	Thomae Gmbh Dr K	Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
KR910009934B1 (ko)	1988-04-15	1991-12-06	다이호오 야꾸힌 고오교오 가부시끼가이샤	카르바모일-2-피롤리디논 화합물
US5028726A (en) *	1990-02-07	1991-07-02	The University Of Vermont And State Agricultural College	Platinum amine sulfoxide complexes
US5780653A (en) *	1995-06-07	1998-07-14	Vivorx Pharmaceuticals, Inc.	Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
WO1998027108A2 (fr)	1996-12-16	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.	Nouveaux composes amide
US6187797B1 (en)	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
ES2324320T3 (es) *	1997-02-10	2009-08-04	Genentech, Inc.	Variantes de herregulina.
US6436966B1 (en)	1997-10-27	2002-08-20	Takeda Chemical Ind., Ltd.	Adenosine A3 receptor antagonists
AU768751B2 (en)	1998-06-18	2004-01-08	Bristol-Myers Squibb Company	Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
ES2250186T3 (es)	1999-09-10	2006-04-16	MERCK & CO., INC.	Inhibidores de tirosina quinasa.
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
CA2401748A1 (fr)	2000-03-29	2001-10-04	Cyclacel Limited	4-heteroaryle-pyrimidines substituees en 2 et leur utilisation dans le traitement de troubles proliferants
KR100589032B1 (ko)	2000-10-20	2006-06-14	에자이 가부시키가이샤	질소 함유 방향환 유도체
ES2254611T3 (es)	2001-05-11	2006-06-16	Pfizer Products Inc.	Derivados de tiazol.
KR100979988B1 (ko)	2001-08-13	2010-09-03	얀센 파마슈티카 엔.브이.	2-아미노-4,5-삼치환 티아졸릴 유도체
WO2003015778A1 (fr)	2001-08-17	2003-02-27	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
EP1430051B1 (fr)	2001-09-28	2006-12-27	Cyclacel Limited	N-(4-(4-methylthiazol-5-yl) pyrimidine-2-yl) -n-phenylamines comme composes a action antiproliferante
AR038703A1 (es) *	2002-02-28	2005-01-26	Novartis Ag	Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
WO2004041813A1 (fr)	2002-10-30	2004-05-21	Vertex Pharmaceuticals Incorporated	Compositions utiles en tant qu'inhibiteurs de rock et d'autres proteines kinases
EP1567487A4 (fr)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
KR20050098244A (ko) *	2003-01-10	2005-10-11	쓰레솔드 파마슈티컬스, 인코포레이티드	2-데옥시글루코오스를 사용한 암 치료 방법
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
US7973169B2 (en)	2003-09-06	2011-07-05	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN1926121B (zh)	2004-01-12	2012-06-13	默克雪兰诺有限公司	噻唑衍生物及其应用
MXPA06015237A (es) *	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
SE0402735D0 (sv)	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
KR101914254B1 (ko) *	2005-02-18	2018-11-02	아브락시스 바이오사이언스, 엘엘씨	치료제의 조합 및 투여 방식, 및 조합 요법
DE102005024157A1 (de)	2005-05-23	2006-11-30	Amedo Gmbh	Nadelpositioniersystem
WO2006125805A1 (fr)	2005-05-24	2006-11-30	Laboratoires Serono S.A.	Derives thiazole et utilisation
ES2399101T3 (es)	2005-05-24	2013-03-25	Merck Serono Sa	Derivados de tiazol y uso de los mismos
DE102005024790A1 (de)	2005-05-26	2006-12-07	Eos Gmbh Electro Optical Systems	Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en)	2005-06-28	2010-02-02	Vertex Pharmaceuticals Incorporated	Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
KR20080080170A (ko)	2005-12-12	2008-09-02	제네랩스 테크놀로지스, 인코포레이티드	Ｎ-(5원 헤테로방향족 고리)-아미도 항바이러스 화합물
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
CA2635830A1 (fr) *	2006-01-23	2007-07-26	Laboratoires Serono S.A.	Derives de thiazole et leur utilisation
US20070259855A1 (en)	2006-04-06	2007-11-08	Udo Maier	Thiazolyl-dihydro-indazole
CN101484452A (zh) *	2006-05-03	2009-07-15	阿斯利康(瑞典)有限公司	噻唑衍生物及其作为抗肿瘤药物的用途
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
FR2904190B1 (fr)	2006-07-25	2008-12-12	Inst Rech Pour Le Dev I R D Et	Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
TW200827368A (en)	2006-11-21	2008-07-01	Genelabs Tech Inc	Amido anti-viral compounds
WO2008124000A2 (fr)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
ES2530431T3 (es)	2007-05-25	2015-03-02	Abbvie Deutschland	Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
US20090004140A1 (en)	2007-06-26	2009-01-01	Yao-Ling Qiu	4-substituted pyrrolidine as anti-infectives
CN104844578B (zh)	2007-07-19	2018-06-19	H.隆德贝克有限公司	5元杂环酰胺及相关的化合物
US20100298286A1 (en)	2007-12-20	2010-11-25	Novartis Ag	Organic Compounds
UY31545A1 (es) *	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
ITMI20072396A1 (it)	2007-12-20	2009-06-21	Dachi S R L	"apparato di chiusura di contenitori di materiale biologico"
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

2009
- 2009-08-09 UA UAA201102837A patent/UA104147C2/uk unknown
- 2009-09-08 EP EP09782777.8A patent/EP2331537B1/fr active Active
- 2009-09-08 KR KR1020117005524A patent/KR101290844B1/ko active Active
- 2009-09-08 CN CN200980135415.7A patent/CN102149711B/zh active Active
- 2009-09-08 AR ARP090103437A patent/AR073369A1/es not_active Application Discontinuation
- 2009-09-08 MX MX2011002597A patent/MX2011002597A/es active IP Right Grant
- 2009-09-08 CA CA2734819A patent/CA2734819C/fr active Active
- 2009-09-08 BR BRPI0918750A patent/BRPI0918750B8/pt active IP Right Grant
- 2009-09-08 GE GEAP200912132A patent/GEP20135991B/en unknown
- 2009-09-08 ES ES09782777.8T patent/ES2560673T3/es active Active
- 2009-09-08 RS RS20150860A patent/RS54476B1/sr unknown
- 2009-09-08 JP JP2011526479A patent/JP5486601B2/ja active Active
- 2009-09-08 MY MYPI20110510 patent/MY151556A/en unknown
- 2009-09-08 HU HUE09782777A patent/HUE025884T2/en unknown
- 2009-09-08 AU AU2009290904A patent/AU2009290904B2/en active Active
- 2009-09-08 PE PE2011000591A patent/PE20110796A1/es active IP Right Grant
- 2009-09-08 ME MEP-2011-21A patent/ME01284B/fr unknown
- 2009-09-08 PT PT97827778T patent/PT2331537E/pt unknown
- 2009-09-08 UY UY0001032096A patent/UY32096A/es active IP Right Grant
- 2009-09-08 SI SI200931344T patent/SI2331537T1/sl unknown
- 2009-09-08 NZ NZ590754A patent/NZ590754A/xx unknown
- 2009-09-08 HR HRP20160014TT patent/HRP20160014T1/hr unknown
- 2009-09-08 EA EA201100447A patent/EA018863B1/ru active Protection Beyond IP Right Term
- 2009-09-08 DK DK09782777.8T patent/DK2331537T3/en active
- 2009-09-08 WO PCT/EP2009/061644 patent/WO2010029082A1/fr not_active Ceased
- 2009-09-08 PL PL09782777T patent/PL2331537T3/pl unknown
- 2009-09-09 TW TW098130412A patent/TWI453206B/zh active
- 2009-09-09 JO JOP/2009/0334A patent/JO3121B1/ar active
- 2009-09-10 US US12/556,964 patent/US8227462B2/en active Active
- 2009-09-10 PA PA20098841901A patent/PA8841901A1/es unknown
2011
- 2011-01-27 ZA ZA2011/00699A patent/ZA201100699B/en unknown
- 2011-01-31 IL IL210976A patent/IL210976A/en active IP Right Grant
- 2011-01-31 TN TN2011000053A patent/TN2011000053A1/fr unknown
- 2011-02-01 CR CR20110059A patent/CR20110059A/es unknown
- 2011-03-01 MA MA33661A patent/MA32604B1/fr unknown
- 2011-03-07 DO DO2011000070A patent/DOP2011000070A/es unknown
- 2011-03-08 HN HN2011000699A patent/HN2011000699A/es unknown
- 2011-03-09 CL CL2011000504A patent/CL2011000504A1/es unknown
- 2011-03-09 NI NI201100049A patent/NI201100049A/es unknown
- 2011-03-10 SV SV2011003853A patent/SV2011003853A/es unknown
- 2011-03-10 CU CU2011000052A patent/CU24000B1/es active IP Right Grant
- 2011-03-10 EC EC2011010880A patent/ECSP11010880A/es unknown
- 2011-03-17 CO CO11033546A patent/CO6351738A2/es active IP Right Grant
- 2011-04-07 SM SM201100019T patent/SMP201100019B/it unknown
2012
- 2012-06-05 US US13/488,589 patent/US8476268B2/en active Active
2013
- 2013-05-24 US US13/901,930 patent/US8710085B2/en active Active
2014
- 2014-02-27 US US14/192,633 patent/US20140186469A1/en not_active Abandoned
2015
- 2015-12-29 CY CY20151101197T patent/CY1117078T1/el unknown
2018
- 2018-06-06 AR ARP180101520A patent/AR112074A2/es not_active Application Discontinuation
2020
- 2020-11-06 NL NL301071C patent/NL301071I2/nl unknown
- 2020-11-16 NO NO2020037C patent/NO2020037I1/no unknown
- 2020-11-18 HU HUS2000044C patent/HUS2000044I1/hu unknown
- 2020-11-20 LU LU00186C patent/LUC00186I2/fr unknown
- 2020-11-24 CY CY2020037C patent/CY2020037I1/el unknown
- 2020-11-25 LT LTPA2020534C patent/LTC2331537I2/lt unknown
- 2020-11-26 FI FIC20200046C patent/FIC20200046I1/fi unknown

Also Published As

Publication number	Publication date
EA201100447A1 (ru)	2011-10-31
US8227462B2 (en)	2012-07-24
UY32096A (es)	2010-04-30
UA104147C2 (uk)	2014-01-10
IL210976A (en)	2014-09-30
CL2011000504A1 (es)	2011-07-15
BRPI0918750B1 (pt)	2020-12-22
US20100105711A1 (en)	2010-04-29
CA2734819A1 (fr)	2010-03-18
JP5486601B2 (ja)	2014-05-07
CA2734819C (fr)	2017-10-24
KR20110038737A (ko)	2011-04-14
US20140005232A1 (en)	2014-01-02
KR101290844B1 (ko)	2013-07-29
NL301071I1 (nl)	2020-11-11
AR112074A2 (es)	2019-09-18
CN102149711B (zh)	2014-09-10
CR20110059A (es)	2011-03-28
MX2011002597A (es)	2011-07-21
RS54476B1 (sr)	2016-06-30
ECSP11010880A (es)	2011-04-29
MA32604B1 (fr)	2011-09-01
SMAP201100019A (it)	2011-05-06
FIC20200046I1 (fi)	2020-11-26
BRPI0918750B8 (pt)	2021-05-25
NI201100049A (es)	2011-07-26
BRPI0918750A2 (pt)	2020-08-04
PT2331537E (pt)	2016-03-03
SI2331537T1 (sl)	2016-02-29
ZA201100699B (en)	2012-08-29
SV2011003853A (es)	2011-05-16
US8476268B2 (en)	2013-07-02
EA018863B1 (ru)	2013-11-29
JP2012502080A (ja)	2012-01-26
LTPA2020534I1 (lt)	2020-12-28
NZ590754A (en)	2012-08-31
NO2020037I1 (no)	2020-11-16
ME01284B (fr)	2013-06-20
TWI453206B (zh)	2014-09-21
US20140186469A1 (en)	2014-07-03
US8710085B2 (en)	2014-04-29
DOP2011000070A (es)	2011-03-31
CN102149711A (zh)	2011-08-10
DK2331537T3 (en)	2016-01-25
LTC2331537I2 (lt)	2022-01-10
MY151556A (en)	2014-06-13
SMP201100019B (it)	2012-01-18
HK1156305A1 (en)	2012-06-08
IL210976A0 (en)	2011-04-28
HUE025884T2 (en)	2016-05-30
US20120263712A1 (en)	2012-10-18
AU2009290904B2 (en)	2012-08-30
ES2560673T3 (es)	2016-02-22
TW201014851A (en)	2010-04-16
PL2331537T3 (pl)	2016-06-30
CU24000B1 (es)	2014-06-27
CY2020037I2 (el)	2021-03-12
LUC00186I2 (fr)	2024-07-01
EP2331537B1 (fr)	2015-10-28
AR073369A1 (es)	2010-11-03
CU20110052A7 (es)	2011-12-28
EP2331537A1 (fr)	2011-06-15
HRP20160014T1 (hr)	2016-02-12
HN2011000699A (es)	2013-12-02
CO6351738A2 (es)	2011-12-20
NL301071I2 (nl)	2020-12-01
AU2009290904A1 (en)	2010-03-18
JO3121B1 (ar)	2017-09-20
HUS2000044I1 (hu)	2020-12-28
PE20110796A1 (es)	2011-11-04
CY1117078T1 (el)	2017-04-05
CY2020037I1 (el)	2021-03-12
PA8841901A1 (es)	2010-06-28
GEP20135991B (en)	2013-12-25
WO2010029082A1 (fr)	2010-03-18

Publication	Publication Date	Title
TN2011000053A1 (en)	2012-09-05	Organic compounds
TN2010000293A1 (en)	2011-11-11	Thiazole derivatives used as pi 3 kinase inhibitors
MX2012000177A (es)	2012-02-28	2-carboxamida-cicloamino-ureas sustituidas.
TN2010000038A1 (en)	2011-09-26	Organic compounds
EP3586631A3 (fr)	2020-03-18	Composition pour la santé des plantes
NZ597517A (en)	2014-04-30	5-fluoropyrimidinone derivatives
PH12015501585A1 (en)	2015-09-21	Manufacturing process for pyrimidine derivatives
UA107445C2 (uk)	2015-01-12	5-фторпіримідинові похідні як фунгіциди
WO2009080705A3 (fr)	2009-09-24	Composés organiques
PH12012501650B1 (en)	2018-11-07	Heterocyclic compound
ZA201002987B (en)	2011-02-23	Tropane compounds
NZ597570A (en)	2014-04-30	N1-acyl-5-fluoropyrimidinone derivatives
WO2011047055A3 (fr)	2011-08-18	Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MX2013011132A (es)	2014-03-12	Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
MX2012000178A (es)	2012-02-28	2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2013002620A (es)	2013-05-09	Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
JO2999B1 (ar)	2016-09-05	مركب ثلاثي حلقي و استخدامه الدوائي
NZ591837A (en)	2013-03-28	Amino acid derivative
DE602008002598D1 (en)	2010-10-28	Cyclohexylderivate
GB0602951D0 (en)	2006-03-29	Organic Compounds
NZ590076A (en)	2012-11-30	Treating plexiform neurofibroma and related tumors
NZ599916A (en)	2013-10-25	5-amino-4-hydroxypentoyl amides
ATE522530T1 (de)	2011-09-15	2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
MX2011012511A (es)	2012-02-28	Anti-oomicetos.